Asthma Treatment in Canada
For adults and adolescents (≥12 years) with asthma in Canada, the preferred approach is inhaled corticosteroid (ICS)-containing therapy—never SABA alone—with the specific regimen determined by asthma severity and symptom frequency. 1, 2
Treatment Algorithm by Severity
Very Mild/Intermittent Asthma (Symptoms <2 times/month)
- First-line option: As-needed low-dose ICS-formoterol (budesonide-formoterol 200-6 μg) taken only when symptoms occur 3, 2
- Alternative: Daily low-dose ICS plus as-needed SABA, though this is less cost-effective in the Canadian healthcare system 3
- The as-needed ICS-formoterol approach saves approximately $9,882 per patient over time while providing equivalent or better outcomes 3
Mild Persistent Asthma (Symptoms ≥2 times/week but not daily)
Two evidence-based options exist with similar efficacy 4, 2:
- Daily low-dose ICS (e.g., beclomethasone 80-250 μg equivalent) with SABA for rescue
- Intermittent ICS therapy: 2-4 puffs albuterol followed by 80-250 μg beclomethasone equivalent every 4 hours as needed for symptoms 4
Important caveat: Patients with poor symptom perception (who underestimate their asthma severity) should receive daily ICS rather than intermittent therapy to avoid undertreatment 4
Moderate to Severe Asthma
- Preferred regimen: Maintenance and Reliever Therapy (MART) with ICS-formoterol combination 1, 5, 6
- Step-up options: ICS/LABA combination therapy, or "triple therapy" with ICS/LABA/LAMA 1
- Severe asthma: Consider biologic therapies when conventional treatment fails 1
Critical Non-Pharmacologic Components
Written Asthma Action Plans
Every patient must receive a personalized written action plan 7, 8. Canadian plans typically use:
- Three-zone, traffic-light design (76% of Canadian plans) 8
- Symptom-based triggers for action
- Clear instructions for medication adjustment and when to seek emergency care
Common pitfall: Many Canadian physicians don't consistently provide action plans despite guideline recommendations 7
Regular Monitoring
- Assess asthma control at every visit using objective criteria, not patient/physician perception alone 7
- Critical finding: 53% of Canadian asthma patients have uncontrolled disease, yet 97% believe they're well-controlled 7
- Use spirometry or peak flow measurements—physician assessment alone overestimates control 7
Patient Education Focus
- Proper inhaler technique (frequently inadequate)
- Recognition of worsening symptoms, especially with common colds 8
- Adherence barriers and medication costs
- Management of comorbidities like allergic rhinitis 1
Special Populations
Children 4-11 Years
- No firm recommendation exists for intermittent vs. daily ICS due to insufficient evidence 4
- Default to daily low-dose ICS for safety in this age group
Children 0-4 Years
- Insufficient evidence for specific recommendations 4
- Requires specialist consultation
Key Practice Points
Avoid these common errors:
- Never prescribe SABA monotherapy—all patients need ICS-containing treatment 6, 9
- Don't rely on patient-reported control; use objective measures 7
- Don't assume MART patients are adequately controlled if they request additional rescue inhalers—this suggests misapplication of MART 5
- Don't delay specialist referral for difficult-to-treat or severe asthma 6
Cost considerations: As-needed budesonide-formoterol is cost-saving for the Canadian public payer system compared to maintenance ICS plus SABA, driven by lower medication and adverse event costs 3